Recent advances in the design of matrix metalloprotease inhibitors

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 4, 2004, Pages 513-535

  Matter, Hans ^a   Schudok, Manfred ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Inhibitor; Lead optimization; Matrix metalloprotease; Selectivity; Structure based design

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

CANCER; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; REVIEW; X RAY CRYSTALLOGRAPHY; ANIMAL; BINDING SITE; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; METHODOLOGY; PHYSIOLOGY;

ALLOSTERIC SITE; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE;

EID: 4644248792     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Stemlicht M, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol (2001) 17:463-516.
2. Woessner JF Jr: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J (1991) 5(8)5145-2154.
3. Woessner JF, Nagase H (Eds): Matrix Metalloproteinases and TIMPs. Oxford University Press, New York, NY, USA (2000). A comprehensive overview of MMP structure and function and their inhibitors.
4. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor U, Birkedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: A review. Crit Rev Oral Biol Med (1993) 4(2):197-250.
5. Murphy G, Docherty AJ: The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol (1992) 7(2):120-125.
6. Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet (1990) 6(4):121-125.
7. Lohmander LS, Hoermer LA, Lark MW: Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum (1993) 36(2):181-189.
8. Murphy G, Hembry RM: Proteinases in rheumatoid arthritis. J Rheumatol Suppl (1992) 32:61-64.
9. Peress N, Perillo E, Zucker S: Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J Neuropathol Exp Neurol (1995) 54(1):16-22.
10. Chang C. Werb Z: The many faces of metalloproteases: Cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol (2001) 11(11):S37-S43.
11. Tosetti F, Ferrari N, De Flora S, Albini A: Angioprevention: Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J (2002) 16(1):2-14.
12. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science (2002) 295(5564):2387-2392. A key paper reviewing the results of clinical trials of MMP inhibitors for the treatment of cancer, and providing general lessons for future research into novel inhibitors in this field.
13. Whittaker M, Floyd CD, Brown P, Gearing AJ: Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev (1999) 99(9):2735-2776.
14. Michaelides MR, Curtin ML: Recent advances in matrix metalloproteinase inhibitors research. Curr Pharm Des (1999) 5(10):787-819.
15. Skiles JW, Gonella NC, Jeng AY: The design, structure and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem (2001) 8(4):425-474. A comprehensive overview of the structural biology and medicinal chemistry of MMP inhibitors.
16. Skotnicki JS, DiGrandi MJ, Levin JI: Design strategies for the identification of MMP-13 and TACE inhibitors. Curr Opin Drug Discovery Dev (2003) 6(5):742-759. A comprehensive review of the latest developments in medicinal chemistry for MMP-13 and TACE inhibition.
17. Nagase H: Matrix metalloproteinases. In: Zinc Metalloproteinases in Health and Disease. Hooper NM (Ed), Tayor and Francis, London, UK (1996):153-204.
18. Pendas AM, Knauper V, Puente XS, Llano E, Mattel MG, Apte S, Murphy G, Lopez-Otin C: Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem (1997) 272(7):4281-4286.
19. Massova I, Kotra LP, Fridman R, Mobashery S: Matrix metalloproteinases: Structures, evolution and diversification. FASEB J(1998) 12(12):1075-1095.
20. Wess G, Urmann M, Sickenberger B: Medicinal chemistry: Challenges and opportunities. Angew Chem Int Ed (2001) 40(18):3341-3350.
21. Bleicher KH, Böhm HJ, Müller K, Alanine AI: Hit and lead generation: Beyond high-throughput screening. Nat Rev Drug Disc (2003) 2(5):369-378.
22. Overall CM, López-Otin C: Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer (2002) 2(9):657-672.
23. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T: Regulation of matrix metalloproteinases: An overview. Mol Cell Biochem (2003) 253(1-2):269-285.
24. Fingleton B: Matrix metalloproteinase inhibitors for cancer therapy: The current situation and future prospects. Exp Opin Ther Targets (2003) 7(3):385-397.
25. Stemlicht MD, Bergers G: Matrix metalloproteinases as emerging targets in anticancer therapy: Status and prospects. Emerging Ther Targets (2000) 4(5):609-633.
26. Wollaston SJ, Kalunian KC: Matrix metalloproteinase inhibitors as therapies for rheumatoid arthritis. In: Modern Therapeutics in Rheumatic Diseases. Tsokos GC (Ed), Humana Press, Totowa, NJ, USA (2002):135-145.
27. Henrotin Y, Sanchez C, Reginster JY: The Inhibition of metalloproteinases to treat osteoarthritis: Reality and new perspectives. Expert Opin Ther Pat (2002) 12(1):29-43. A significant contribution highlighting the impact of MMP inhibitors on the treatment of OA.
28. Pelletier JP: Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis. Osteoarthritis Cartilage (2003) 12(Suppl A):S63-S68.
29. Skotnicki JS, Levin JI: TNF-α-converting enzyme (TACE) as a therapeutic target. Ann Rep Med Chem (2003) 38:153-162.
30. Maskos K, Fernandez-Catalan C, Huber R, Bourenkov GP, Bartunik H, Ellestadt GA, Reddy P, Wolfson MF. Rauch CT, Castner BJ, Davis R et al: Crystal structure of the catalytic domain of human tumor necrosis factor-α- converting enzyme. Proc Natl Acad Sci USA (1998) 95(7):3408-3412. Publication of the first X-ray crystal structure of TACE.
31. Peterson JT, Li H: Matrix metalloproteinase inhibitor development for the treatment of heart failure. Drug Dev Res (2002) 55(1):29-44.
32. Sierevogel MJ, Pasterkamp G, de Kleijn DP, Strauss BH: Matrix metalloproteinases: A therapeutic target in cardiovascular disease. Curr Pharm Des (2003) 9(13):1033-1040.
33. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, Olivotti L, Rossettin P, Barsotti A, Ghigliotti G: Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest (2003) 33(8):648-656.
34. Lindsey ML: MMP induction and inhibition in myocardial infarction. Heart Failure Rev (2004) 9(1):7-19.
35. Belvisi MG, Bottomley KM: The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): A therapeutic role for inhibitors of MMPs? Inflamm Res (2003) 52(3):95-100.
36. Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K: Structural properties of matrix metalloproteinases. Cell Mol Life Sci (1999) 55(4):639-652. A significant contribution highlighting many different aspects of MMP structures and complexes with their respective inhibitors.
37. Borkakoti N: Matrix metalloproteases: Variations on the theme. Prog Biophys Mol Biol (1998) 70(1):73-94. Highly interesting overview of structural biology aspects for MMP inhibition and comparison with other metalloproteases.
38. Borkakoti N: Structural studies on matrix metalloproteinases. J Mol Med (2000) 78(5):261-268.
39. Bode W, Reinemer P, Huber R, Kleine T, Schnierer S, Tschesche H: The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J (1994) 13(6):1263-1269.
40. 73 active-site complex in latency and a 'cysteine switch' mechanism for activation. Proc Natl Acad Sci USA (1990) 87(1):364-368.
41. Morgunova E, Tuuttila A, Bergmann U, Isupov M, Lindqvist Y, Schneider G, Tryggvason K: Structure of human pro-matrix metalloproteinase-2: Activation mechanism revealed. Science (1999) 284(5420):1667-1670.
42. Borkakoti N. Winkler FK, Williams DH, D'Arcy A, Broadhurst MJ, Brown PA, Johnson WH, Murray EJ: Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nat Struct Biol (1994) 1(2):106-110.
43. Massova I, Kotra LP, Mobashery S: Structural insight into the binding motifs for the calcium ion and the non-catalytic zinc in matrix metalloproteinases. Bioorg Med Chem Lett (1998) 8(7):853-858.
44. Lovejoy B, Hassell AM, Luther MA, Weigl D, Jordan SR: Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself. Biochemistry (1994) 33(27):8207-8217.
45. Johnson LL, Pavlovsky AG, Johnson AR, Janowicz JA, Man CF, Ortwine DF, Purchase CF 2nd, White AD, Hupe DJ: A rationalization of the acidic pH dependence for stromelysin-1 (matrix metalloproteinase-3) catalysis and inhibition. J Biol Chem (2000) 275(15):11026-11033. Important biochemical insights into the MMP-3 catalytic mechanism.
46. Gall AL, Ruff M, Kannan R, Cuniasse P, Yiotakis A, Dive V, Rio MC, Basset P, Moras D: Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state. J Mol Biol (2001) 307(2):577-586.
47. Bertini I, Calderone V, Fragai M, Luchinat C, Mangani S, Temi B: X-ray structures of binary and ternary enzyme-product-inhibitor complexes of matrix metalloproteinases. Angew Chem (2003) 115(23):2777-2780. The publication of 3D protein structures for mimicking MMP-substrate and product complexes which provides a greater understanding of the prerequisites for product binding.
48. Nagase H, Fields GB: Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Biopolymers (1996) 40(4):399-416.
49. Burley SK, Petsko GA: Aromatic-aromatic interaction: A mechanism of protein structure stabilization. Science (1985) 229(4708):23-28.
50. Gomis-Ruth FX, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, Yoshida N, Nagase H, Brew K, Bourenkov GP, Bartunik H et al: Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature (1997) 389(6646):77-81.
51. Bergner A, Günther J, Hendlich M, Klebe G, Verdonk M: Use of Relibase for retrieving complex three-dimensional interaction patterns including crystallographic packing effects. Biopolymers (2002) 61(2):99-110.
52. Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P et al: Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: A structure-activity study. J Med Chem (1999) 42(14):2610-2620.
53. Lovejoy B, Welch AR, Carr S, Luong C, Broka C, Hendricks RT, Campbell JA, Walker KA, Martin R, Van Wart H, Browner MF: Crystal structures of MMP-1 and -13 reveal the crystal structural basis for selectivity of collagenase inhibitors. Nat Struct Biol (1999) 6(3):217-221. Important publication demonstrating the impact of X-ray crystal structure analysis on understanding selectivity differences in MMPs.
54. Browner MF, Smith WW, Castelhano AL: Matrilysin-inhibitor complexes: Common themes among metalloproteases. Biochemistry (1995) 34(20):6602-6610.
55. Moy FJ, Pisano MR, Chanda PK, Urtano C, Killar LM, Sung ML, Powers R: Assignments, secondary structure and dynamics of the inhibitor-free catalytic fragment of human fibroblast collagenase. J Biomol NMR (1997) 10(1):9-19.
56. Moy FJ, Chanda PK, Chen J, Cosmi S, Edris W, Levin JI, Rush TS, Wilhelm J, Powers R: Impact of mobility on structure-based drug design for the MMPs. J Am Chem Soc (2002) 124(43):12658-12659. Important contribution to studies into the effect of protein binding site dynamics on inhibitor binding in the MMP family using NMR spectroscopy.
57. Källblad P, Willems HM, Dean PM: Virtual screening of reagents in a highly flexible site. In: EuroQSAR2002: Designing Drugs and Crop Protectants: Processes, Problems and Solutions. Ford M, Livingstone D, Dearden J, Van de Waterbeemd H (Eds), Blackwell Publishing, Oxford, UK (2003):55-58.
58. Källblad P, Todorov NP, Willems HM, Alberts IL: Receptor flexibility in the in silico screening of reagents in the S1' pocket of human collagenase. J Med Chem (2004) 47(11):2761-2767.
59. Matter H, Schwab W, Barbier D, Billen G, Haase B, Neises B, Schudok M, Thorwart W, Brachvogel V, Lönze P, Weithmann KU: Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field and X-ray structure analysis. J Med Chem (1999) 42(11):1908-1920. Study demonstrating that appropriate substituents in S1' can compensate for a loss of binding affinity resulting from changes to the zinc-binding group.
60. Matter H, Schwab W: Affinity and selectivity of matrix metalloproteinase inhibitors: A chemometrical study from the perspective of ligands and proteins. J Med Chem (1999) 42(22):4506-4523.
61. Goodford PJ: A computational procedure for determining energetically favorable binding sites on biologically important macromotecules. J Med Chem (1985) 28(7):849-857.
62. Gohlke H, Hendlich M, Klebe G: Knowledge-based scoring function to predict protein-ligand interactions. J Mol Biol (2000) 295(2):337-356.
63. Kastenholz MA, Pastor M, Cruciani G, Haaksma EE, Fox T: GRID/CPCA: A new computational tool to design selective ligands. J Med Chem (2000) 43(16):3033-3044.
64. Terp GE, Cruciani G, Christensen IT, Jorgensen FS: Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. J Med Chem (2002) 45(13)5675-2684. Description of a novel approach to finding selectivity differences in the MMP family using a combination of force field-based descriptors and statistical approaches. Several interesting differences within all major MMP subsites are highlighted.
65. Reiter LA, Rizzi JP, Pandit J, Lasut MJ, McGahee SM, Parikh VD, Blake JF, Danley DE, Laird ER, Lopez-Anaya A, Lopresti-Morrow LL et al: Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket. Bioorg Med Chem Lett (1999) 9(2):127-132.
66. Finzel BC, Baldwin ET, Bryant GL Jr, Hess GF, Wilks JW, Trepod CM, Mott JE, Marshall VP, Petzold GL, Poorman RA, O'Sullivan TJ et al: Structural characterization of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity. Protein Sci (1998) 7(10):2118-2126.
67. Matter H, Naumann T, Pirard B: Target family landscapes to match ligand selectivity with binding site topology in chemical biology. In: EuroQSAR2002: Designing Drugs and Crop Protectants: Processes, Problems and Polutions. Ford M, Livingstone D, Dearden J, Van de Waterbeemd H (Eds), Blackwell Publishing. Oxford, UK (2003):183-185.
68. Lukacova V, Zhang Y, Mackov M, Baricic P, Raha S, Calva JA, Balaz S: Similarity of binding sites of human matrix metalloproteinases. J Biol Chem (2004) 279(14):14194-14200.
69. Bertini I, Calderone V, Fragai M, Luchinat C, Mangani S, Terni B: Crystal structure of the catalytic domain of human matrix metalloproteinase 10. J Mol Biol (2004) 336(3)707-716.
70. Dhanaraj V, Ye QZ, Johnson LL, Hupe DJ, Ortwine DF, Dunbar JB Jr, Rubin JR, Pavlovsky A, Humblet C, Blundell TL: X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure (1996) 4(4):375-386.
71. Rowsell S, Hawtin R, Minshull CA, Jepson H, Brockbank SM, Barratt DG, Slater AM, McPheat WL, Waterson D, Henney AM, Pauptit RA: Crystal structure of human MMP-9 in complex with a reverse hydroxamate inhibitor. J Mol Biol (2002) 319(1):173-181.
72. Lang R, Kocourek A, Braun M, Tschesche H, Huber R, Bode W, Maskos K: Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure. J Mol Biol (2001) 312(4):731-742. High-resolution X-ray structure of an MMP-inhibitor complex at atomic resolution provides unprecedented insights into protein-ligand interactions.
73. Nar H, Werte K, Bauer MM, Dollinger H, Jung B: Crystal structure of human macrophage elastase (MMP-12) In complex with a hydroxamic acid inhibitor. J Mol Biol (2001) 312(4):743-751.
74. Fernandez-Catalan C, Bode W, Huber R, Turk D, Calvete JJ, Lichte A, Tschesche H, Maskos K: Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J (1998) 17(17):5238-5248.
75. Parker MH, Lunney EA, Ortwine DF, Pavlovsky AG, Humblet C, Brouillette CG: Analysis of the binding of hydroxamic acid and carboxylic acid inhibitors to the stromelysin-1 (matrix metalloproteinase-3) catalytic domain by isothermal titration calorimetry. Biochemistry (1999) 38(41):13592-13601. Important paper studying the protein-ligand binding event on a biophysical basis. It illustrates the value of thermodynamic profiles generated by ITC In discovering binding interactions that might be undetected, when relying on binding affinities alone, in structure-based design.
76. Parker MH, Ortwine DF, O'Brien PM, Lunney EA, Banotai CA, Mueller WT, McConnell P, Brouillette CG: Stereoselective binding of an enantiomeric pair of stromelysin-1 inhibitors caused by conformational entropy factors. Bioorg Med Chem Lett (2000) 10(21):2427-2430.
77. a of ligands coordinated to the catalytic zinc ion. J Am Chem Soc (2002) 124(37):11004-11007.
78. Muri EM, Nieto MJ, Sindelar RD, Williamson JS: Hydroxamic acids as pharmacological agents. Curr Med Chem (2002) 9(17):1631-1653.
79. Lou B, Yang K: Molecular diversity of hydroxamic acids: Part II. Potential therapeutic applications. Mini Rev Med Chem (2003) 3(6):609-620.
80. Michaelides MR, Deilaria JF, Gong J, Holms J, Bouska JJ, Stacey J, Wada CK, Heyman HR, Curtin ML, Guo Y, Goodfellow CL et al: Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors. Bioorg Med Chem Lett (2001) 11(12):1553-1556.
81. Singh J, Conzentino P, Cundy P, Gainor JA, Gilliam CL, Gordon TD, Johnson JA, Morgan BA, Schneider ED: Relationship between structure and bioavailability in a series of hydroxamate based metalloprotease inhibitors. Bioorg Med Chem Lett (1995) 5(4):337-342.
82. Summers JB, Gunn BP, Mazdiyasni H, Goetze AM, Young PR, Bouska JB, Dyer RD, Brooks DW, Carter GW: In vivo characterization of hydroxamic acid Inhibitors of 5-lipoxygenase. J Med Chem (1987) 30(11):2121-2126.
83. Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF et al: Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4- hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J Med Chem (2003) 46(12):2376-2396. Detailed description of one specific series including all data from chemistry, SAP, X-ray crystallography, biology (from enzyme to cellular systems to animal models including ACL-model) and PK studies.
84. Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH et al: Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J Med Chem (2002) 45(1):219-232. Detailed description of the chemical lead optimization process. This contribution includes many SAR and PK data.
85. Hajduk PJ, Shuker SB, Nettesheim DG, Craig R, Augeri DJ, Betebenner D, Albert DH, Guo Y, Meadows RP, Xu L, Michaelides M et al: NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. J Med Chem (2002) 45(26):5628-5639.
86. Matter H, Schudok M, Schwab W, Thorwart W, Barbier D, Billen G, Haase B, Neises B, Weithmann KU, Wollmann T: Tetrahydroisoquinoline-3-carboxylate based matrix metalloproteinase inhibitors: Design, synthesis and structure-activity relationship. Bioorg Med Chem (2002) 10(11):3529-3544.
87. Xue C-B, He X, Roderick J, Corbett RL, Duan JJW, IJu R-Q, Covington MB, Newton RC, Trzaskos JM, Magolda RL, Wexler RR et al: Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-á converting enzyme inhibitors. Part 1: Lead identification. Bioorg Med Chem Lett (2003) 13(24):4293-4297.
88. Duan JJ, Lu Z, Xue C-B, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu R-Q, Covington MB, Magolda RL, Newton RC et al: Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-α converting enzyme (TACE). Bioorg Med Chem Lett (2003) 13(12):2035-2040. Description of an interesting MMP inhibitor scaffold and side chain which exhibits high specificity for TACE.
89. Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu R-Q, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD et al: Discovery of γ-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor-α converting enzyme: Design, synthesis, and structure-activity relationships. J Med Chem (2002) 45(23):4954-4957. Review of an interesting series with high specificity for TACE.
90. Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu R-Q, Covington MB, Qian M et al: Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-α converting enzyme Inhibitors. J Med Chem (2003) 46(10):1811-1823.
91. Cherney RJ, Meyer DT, Wasserman ZR, Hardman KD, Liu R-Q, Covington MB, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL et al: Design, synthesis, and evaluation of sultam hydroxamates as novel MMP inhibitors. 226th ACS National Meeting, New York, NY, USA (2003):MEDI 114. Impressive, simple cyclic structures with promising properties, synthesized using a cyclization concept and starting from known series.
92. Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu R-Q, Covington MB, Tortorella MD, Amer EC, Qian M et al: Potent and selective aggrecanase Inhibitors containing cyclic P1 substituents. Bioorg Med Chem Lett (2003) 13(7):1297-1300.
93. Sawa M: Phosphonamide-based metalloproteinase inhibitors: A new approach to the development of safer metalloproteinase inhibitors. Curr Med Chem: Anti-Inflammatory Anti-Allergy Agents (2003) 2(4):367-378.
94. Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E et al: New type of metalloproteinase inhibitor: Design and synthesis of new phosphonamide-based hydroxamic acids. J Med Chem (2002) 45(4):919-929. Report providing a detailed description of a series of phosphonamides as analogs of sulfonamides, in terms of SAR, chemistry and properties such as biology and NMR data.
95. Sawa M, Tsukamoto T, Kiyoi T, Kurokawa K, Nakajima F, Nakada Y, Yokota K, Inoue Y, Kondo H, Yoshino K: New strategy for antedrug application: Development of metalloproteinase inhibitors as antipsoriatic drugs. J Med Chem (2002) 45(4):930-936.
96. Moriyama H, Tsukida T, Inoue Y, Yokota K, Yoshino K, Kondo H, Miura N, Nishimura S: Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. J Med Chem (2004) 47(8):1930-1938.
97. Letavic MA, Axt MZ, Barberia JT, Carty TJ, Dantey DE, Geoghegan KF, Halim NS, Hoth LR, Kamath AV, Laird ER, Lopresti-Morrow LL et al: Synthesis and biological activity of selective pipecolic acid-based TNF-α converting enzyme (TACE) inhibitors. Bioorg Med Chem Lett (2002) 12(10):1387-1390.
98. Letavic MA, Barberia JT, Carty TJ, Hardink JR, Liras J, Lopresti-Morrow LL, Mitchell PG, Noe MC, Reeves LM, Snow SL, Stam EJ et al: Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-α converting enzyme inhibitors. Bioorg Med Chem Lett (2003) 13(19):3243-3246.
99. Fray MJ, Dickinson RP, Huggins JP, Occleston NL: A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem (2003) 46(16):3514-3525.
100. Chen JJ, Dewdney N, Un X, Martin RL, Walker KA, Huang J, Chu F, Eugui E, Mirkovich A, Kim Y, Sarma K et al: Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs. Bioorg Med Chem Lett (2003) 13(22):3951-3954.
101. Beck G, Bottomley G, Bradshaw D, Brewster M, Broadhurst M, Devos R, Hill C, Johnson W, Kim H-J, Kirtland S, Kneer J et al: (E)-2(R)-[1(S)- (Hydroxycarbamoyl)-4-prienyl-3-butenyl]-2′-isobutyl-2′- (methanesurfonyl)-4-methylvaterohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-α convertase. J Pharmacol Exp Ther (2002) 302(1):390-396.
102. Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA et al: Synthesis and structure-activity relationship of α-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J Med Chem (2003) 46(12):2361-2375.
103. Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA et al: Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors. Bioorg Med Chem Lett (2003) 13(8):1487-1490.
104. Chen JM, Jin G, Sung A, Levin JI: Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetytenic P1' groups. Bioorg Med Chem Lett (2002) 12(8):1195-1198.
105. Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ et al: Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group. Bioorg Med Chem Lett (2002) 12(8):1199-1202.
106. Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G et al: Benzodiazepine inhibitors of the MMPs and TACE. Bioorg Med Chem Lett (2002) 12(20):2867-2870.
107. Zhang Y, Xu J, Levin J, Hegen M, Li G, Robertshaw H, Brennan F, Cummons T, Clarke D, Vansell N, Nickerson-Nutter C et al: Identification and characterization of 4-[[4-(2-butynyloxy)-phenyl]sulfonyl]-N-hxdroxy-2,2- dimethyl-(3S)-thiomoroholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-α-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Exp Ther (2004) 309(1):348-355.
108. Grams F, Brandstetter H, Engh RA, Glitz D, Krell HW, Livi V, Menta E, Moroder L, Muller JCD, Graf von Roedern E, Zimmermann G: Research on MMP inhibitors with unusual scaffolds. In: Matrix Metalloproteinase Inhibitors in Cancer Therapy. Humana Press Inc, Totowa, NJ, USA (2001):223-243.
109. Brandstetter H, Grams F, Glitz D, Lang A, Huber R, Bode W, Krell HW1 Engh RA: The 1.8-Å crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition. J Biol Chem (2001) 276(20):17405-17412.
110. Grams F, Brandstetter H, D'Alò S, Geppert D, Krell HW, Leinert H, Livi V, Menta E, Oliva A, Zimmermann G: Pyrimidine-2,4,6-triones: A new effective and selective class of matrix metalloproteinase inhibitors. Biol Chem (2001) 382(8):1277-1285.
111. Stockman BJ, Waldon DJ, Gates JA, Scahill TA, Kloosterman DA, Mizsak SA, Jacobsen J, Belonga KL, Mitchell MA, Mao B, Petke JD et al: Solution structures of stromelysin complexed to thiadiazole inhibitors. Protein Sci (1998) 7(11):2281-2286.
112. Finkel BC, Baldwin ET, Bryant GL, Hess GF, Wilks JW, Trepod CM, Mott JE, Marshall VP, Petzold GL, Poorman RA, O'Sullivan TJ et al: Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity. Protein Sci (1998) 7(10):2118-2126.
113. Kuo MS, Yurek DA, Mizsak SA, Prairie MD, Mattern SJ, DeKoning TF: Isolation and identification of a major metabolite of PNU-107859, an MMP inhibitor from the biliary fluid of rats. J Pham Sci (1999) 88(7):705-708.
114. Rizzo RC, Toba S, Kuntz ID: A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from Generalized Born Molecular Dynamics simulations. J Med Chem (2004) 47(12):3065-3074.
115. Schroeder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H: Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. J Med Chem (2001) 44(20):3231-3243.
116. Wang X, Choe Y, Craik CS, Ellman JA: Design and synthesis of novel inhibitors of gelatinase B. Bioorg Med Chem Lett (2002) 12(16):2201-2204.
117. Puerta DT, Cohen SM: Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors. Inorg Chem (2003) 42(11):3423-3430.
118. Puerta DT, Schames JR, Henchman RH, McCammon JA, Cohen SM: From model complexes to metalloprotein Inhibition: A synergistic approach to structure-based drug discovery. Angew Chem Int Ed (2003) 42(32):3772-3774.